Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Calliditas
Mandate

Vinge advises Calliditas

June 10, 2020 Capital Markets and Public M&A

Vinge advises Calliditas Therapeutics in connection with its capital raising and listing on The Nasdaq Global Select Market in United States.

The trading on The Nasdaq Global Select Market in United States began on 5 June 2020. The total value of the global offering amounts to approximately USD 103.5 million, assuming that the over allotment option is fully exercised.

Calliditas is a specialty pharmaceutical company, focused on the development and commercialization of the product candidate Nefecon, intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.

Vinge’s team consisted of Dain Hård Nevonen, Sofie Bjärtun, Nils Fredrik Dehlin, Hampus Olsson and Julia Hirschberg.

Related

Vinge advises Platzer on a combined asset swap transaction with the Port of Gothenburg concerning properties in Arendal

 Vinge has advised Platzer on a combined asset swap transaction with the Port of Gothenburg comprising the sale of the property Arendal 1:28, parts of the properties Arendal 1:29 and Arendal 1:31, and the acquisition of part of the property Arendal 764:291.
April 08, 2026

Vinge has advised SEB, Swedbank and Danske Bank in connection with a bridge facility to Catena

 Vinge has advised Skandinaviska Enskilda Banken AB (publ), Swedbank AB (publ) and Danske Bank A/S in their capacities as mandated lead arrangers and bookrunners in connection with a term loan bridge facility in an aggregate amount of SEK 4,360,000,000, EUR 195,000,000 and DKK 170,000,000 to Catena AB (publ).
April 02, 2026

Vinge advises the founders of Nordic Knots in connection with the investment in the company by Imaginary Ventures and other investors

Vinge has advised the founders of Nordic Knots in connection with an investment in the company led by Imaginary Ventures, with additional investors including Creades, IRIS Ventures and St Dominique Capital.
April 02, 2026